Ultimate
Predictability

genOway offers preclinical models and solutions to bio-pharmaceutical and academic researchers for ultimate predictability.
Improve PK analysis of therapeutics with extended half-life with the genO-hSA/hFcRn mouse model
Learn more
Vir Biotechnology used the genO-hFcγR model to test anti-malarial antibodies
Learn more
Predict CRS and avoid clinical failure with the genO-BRGSF-HIS model
Learn more

Ensuring the ultimate predictability of your research

At genOway, we recognize the crucial role that preclinical research plays in the success of new therapies in clinical settings. Our team of experts brings together decades of experience in designing genetically modified models and a profound understanding of biological physiology to provide unmatched preclinical solutions.

Our collaborative approach, rooted in a deep understanding of your specific needs and complemented by our expertise, strives to define the best solution to predict the success of your research. Join us on a journey of scientific advancement for the benefit of human health.

  • 28
    countries worldwide
  • 380
    academic institutions
  • 13
    EU projects
  • 170
    Life Sciences companies
  • 17
    of the Top 20 pharma

Catalog models

Explore our comprehensive catalog of preclinical models, featuring genetically modified mice, rats, and cell lines. All our models were designed and validated with the highest standards of excellence to ensure the ultimate predictability of your research.

Learn more

Customized models

Explore our service for creating genetically modified mouse, rat, and cell line models perfectly adapted to answer your scientific questions. With an in-depth understanding of your needs, our team of scientific experts, committed to your side, will accompany you throughout this journey.

Learn more
Our latest resources and publications
Posters
Scientific Articles
Commentaries
(Oncodesign) Novel PSMA+ and FAP+ mouse models to support the development of novel molecular radiotherapy agents

New radiotherapy development with genO-BRGSF

May 2025
(Seismic) S-4321, a novel dual-cell bidirectional PD-1:FcγRIIb selective agonist antibody for the treatment of autoimmune disease

Autoimmune disease treatment with genO-hPD-1

May 2025
genO-hCCR8/hCCL1 humanized model for efficacy assessment of CCR8/CCL1-targeting therapies

CCR8/CCL1-targeting therapies assessment

Apr 2025
Show all posters
Advancing In Vivo Detection of T‑Cell Function: Development and Preclinical Evaluation of ⁸⁹Zr‑Ivuxolimab, a Human OX40 PET Tracer

J Nucl Med

2025
Analysis of Fc-dependent effector functions of anti-malaria circumsporozoite protein antibodies

Microbiol Spectr

2025
ANV600 is a novel PD-1 targeted IL-2Rβγ agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy

J Immunother Cancer

2025
Show all scientific articles
Targeted immunotherapy against autoreactive B cells in autoimmune diseases

T-cell engagers in immunotherapies

10 min read
-
Mar 2025
A radiolabeled VISTA antibody for imaging VISTA expression

hVISTA - antibodies & PET imaging

7 min read
-
Oct 2024
New CD4-specific minibodies to predict cancer treatment outcomes

CD4 for cancer treatment outcomes

5 min read
-
Oct 2024
Show all commentaries
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe